The effective management of cardiovascular disease is one of the greatest medical challenges of the 21st century. Increased understanding of its pathophysiology, growing awareness of the importance of lifestyle interventions and development of various pharmaceutical agents with differing targets have resulted in many successes, but the overall war against cardiovascular disease has yet to be won.
Left ventricular hypertrophy (LVH) is one of the first, and arguably the most important, signs of cardiovascular targetorgan damage. The structural changes in the heart resulting from chronic pressure or volume overload are known to be ominous predictors of future, potentially fatal, cardiovascular events. Many asymptomatic individuals, however, remain unaware of their poor prognosis until coronary heart disease or congestive heart failure is diagnosed or a stroke occurs; it is only then that the true seriousness of their health problems are fully appreciated. For some individuals, the initial cardiovascular event is non-fatal, but can seriously affect their quality of life. Regrettably, however, all too often the first event is fatal.
Blood pressure is the strongest independent risk factor for LVH: approximately one-third of people with hypertension have LVH. Thus, lowering of blood pressure is a logical and widely accepted approach to regress LVH, reduce arrhythmias, improve diastolic function, preserve systolic function, improve coronary reserve, and ultimately improve prognosis. Extensive clinical data show that use of any major class of anti-hypertensive agents may help reduce LV mass. Some drug classes may prove more effective than others, however.
The mechanisms involved in the development of LVH are still not fully understood, but angiotensin II is clearly implicated. Hence, targeting the reninangiotensin -aldosterone system (RAAS) may confer additional benefits to those achieved by the lowering of blood pressure using other anti-hypertensive drugs. Accumulating evidence suggests that the well-tolerated angiotensin II receptor blockers are one of the most effective classes of antihypertensive agents in achieving regression of LVH because of their mode of action.
The pharmacological features of the angiotensin II receptor blocker telmisartan make it an attractive therapeutic option for the management of LVH, with the potential for long-term outcomes benefit. The preclinical and clinical evidence for the favourable effects of telmisartan is now being reinforced by additional clinical studies reported in this supplement. Furthermore, the blood pressure-independent effects of telmisartan in the management of cardiovascular disease are currently being examined in the ground-breaking ONgoing Telmisartan Alone and in combination with the Ramipril Global Endpoint Trial (ONTARGET) Programme. A substudy, the design of which is described in the final article within this supplement, is examining Introduction B DAHLÖF 1 AND R DEVEREUX 2 1 Sahlgrenska University Hospital, Ostra Hospital, Gothenburg, Sweden; 2 Weill Medical College of Cornell University, New York, NY, USA
